Global Checkpoint Inhibitors for Treating Cancer Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Checkpoint Inhibitors for Treating Cancer market size was valued at US$ 65724 million in 2025 and is forecast to a readjusted size of US$ 105028 million by 2032 with a CAGR of 7.4% during review period.
Checkpoint inhibitors for treating cancer are immuno-oncology medicines that block inhibitory immune-regulatory pathways, principally PD-1, PD-L1, CTLA-4 and LAG-3, allowing activated T cells to retain or recover their ability to identify and attack malignant cells. Checkpoint inhibitors includes commercial monoclonal antibodies, bispecific antibodies, single-domain antibody fusion products, fixed-dose antibody combinations and antibody-enzyme coformulations approved for cancer treatment.
Upstream of checkpoint inhibitors include mammalian cell lines, cell-culture media, single-use bioreactor assemblies, chromatography resins, filtration membranes, sterile excipients, glass vials, prefilled delivery components and cold-chain packaging. Manufacturing requires validated biologic production systems, aseptic fill-finish capacity, regulatory-grade analytical testing and continuous comparability control. Downstream customers consist primarily of oncology hospitals, specialist cancer centers, infusion clinics, public health systems, private insurers, government reimbursement agencies and national or regional pharmaceutical procurement platforms. Purchasing normally occurs through hospital formulary inclusion, national reimbursement negotiation, annual tendering, group purchasing contracts and long-term supply agreements. A representative producer gross margin is estimated at 79.0%, supported by biologic manufacturing barriers, regulatory exclusivity, extensive clinical evidence, broad approved labels, established physician familiarity and the high cost of switching treatment protocols.
In the current market, global production of Checkpoint inhibitors is around 27.5 million Units, with an average selling price of about 2,315 USD per Unit. Top 5 suppliers control approximately 91 percent of global revenue CR5. Merck leads through Keytruda and its subcutaneous formulation, followed by Bristol Myers Squibb with the Opdivo, Yervoy and Opdualag franchise. AstraZeneca, Roche and Regeneron form the remainder of the top five. North America remains the largest revenue market because of high net treatment prices and broad use in earlier treatment settings. Europe is the second-largest revenue region, while China has a substantially higher share of treatment volume than revenue because domestic PD-1, PD-L1 and bispecific products are sold at lower net prices following reimbursement negotiation. Japan is also material through Ono Pharmaceutical?s Opdivo franchise.
From 2026 through 2032, treatment volume is expected to increase faster than revenue as checkpoint therapy moves further into neoadjuvant, adjuvant and maintenance settings while average prices decline. Subcutaneous versions of established antibodies should reduce infusion-chair time and hospital administration costs, but they will also intensify life-cycle competition among incumbent suppliers. Chinese producers are expected to expand beyond the domestic market through international approvals, licensing agreements and lower-cost supply, particularly in lung, gastric, esophageal and hepatobiliary cancers. Bispecific products combining PD-1 with CTLA-4, VEGF or other immune pathways will increase their share, although only products demonstrating clear survival or safety advantages are likely to achieve broad reimbursement. Patent expiry around leading PD-1 franchises, biosimilar development, national price negotiation and payer restrictions will place sustained pressure on ASP. Competition will also come from antibody-drug conjugates, targeted therapies, radioligand treatments and biomarker-selected combination regimens.
This report is a detailed and comprehensive analysis for global Checkpoint Inhibitors for Treating Cancer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Checkpoint Target and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Checkpoint Inhibitors for Treating Cancer market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Checkpoint Inhibitors for Treating Cancer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Checkpoint Inhibitors for Treating Cancer market size and forecasts, by Checkpoint Target and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Checkpoint Inhibitors for Treating Cancer market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Checkpoint Inhibitors for Treating Cancer market is split by Checkpoint Target and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Checkpoint Target, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Checkpoint Target
Chapter 1, to describe Checkpoint Inhibitors for Treating Cancer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Checkpoint Inhibitors for Treating Cancer, with price, sales quantity, revenue, and global market share of Checkpoint Inhibitors for Treating Cancer from 2021 to 2026.
Chapter 3, the Checkpoint Inhibitors for Treating Cancer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Checkpoint Inhibitors for Treating Cancer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Checkpoint Target and by Application, with sales market share and growth rate by Checkpoint Target, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Checkpoint Inhibitors for Treating Cancer market forecast, by regions, by Checkpoint Target, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Checkpoint Inhibitors for Treating Cancer.
Chapter 14 and 15, to describe Checkpoint Inhibitors for Treating Cancer sales channel, distributors, customers, research findings and conclusion.
Checkpoint inhibitors for treating cancer are immuno-oncology medicines that block inhibitory immune-regulatory pathways, principally PD-1, PD-L1, CTLA-4 and LAG-3, allowing activated T cells to retain or recover their ability to identify and attack malignant cells. Checkpoint inhibitors includes commercial monoclonal antibodies, bispecific antibodies, single-domain antibody fusion products, fixed-dose antibody combinations and antibody-enzyme coformulations approved for cancer treatment.
Upstream of checkpoint inhibitors include mammalian cell lines, cell-culture media, single-use bioreactor assemblies, chromatography resins, filtration membranes, sterile excipients, glass vials, prefilled delivery components and cold-chain packaging. Manufacturing requires validated biologic production systems, aseptic fill-finish capacity, regulatory-grade analytical testing and continuous comparability control. Downstream customers consist primarily of oncology hospitals, specialist cancer centers, infusion clinics, public health systems, private insurers, government reimbursement agencies and national or regional pharmaceutical procurement platforms. Purchasing normally occurs through hospital formulary inclusion, national reimbursement negotiation, annual tendering, group purchasing contracts and long-term supply agreements. A representative producer gross margin is estimated at 79.0%, supported by biologic manufacturing barriers, regulatory exclusivity, extensive clinical evidence, broad approved labels, established physician familiarity and the high cost of switching treatment protocols.
In the current market, global production of Checkpoint inhibitors is around 27.5 million Units, with an average selling price of about 2,315 USD per Unit. Top 5 suppliers control approximately 91 percent of global revenue CR5. Merck leads through Keytruda and its subcutaneous formulation, followed by Bristol Myers Squibb with the Opdivo, Yervoy and Opdualag franchise. AstraZeneca, Roche and Regeneron form the remainder of the top five. North America remains the largest revenue market because of high net treatment prices and broad use in earlier treatment settings. Europe is the second-largest revenue region, while China has a substantially higher share of treatment volume than revenue because domestic PD-1, PD-L1 and bispecific products are sold at lower net prices following reimbursement negotiation. Japan is also material through Ono Pharmaceutical?s Opdivo franchise.
From 2026 through 2032, treatment volume is expected to increase faster than revenue as checkpoint therapy moves further into neoadjuvant, adjuvant and maintenance settings while average prices decline. Subcutaneous versions of established antibodies should reduce infusion-chair time and hospital administration costs, but they will also intensify life-cycle competition among incumbent suppliers. Chinese producers are expected to expand beyond the domestic market through international approvals, licensing agreements and lower-cost supply, particularly in lung, gastric, esophageal and hepatobiliary cancers. Bispecific products combining PD-1 with CTLA-4, VEGF or other immune pathways will increase their share, although only products demonstrating clear survival or safety advantages are likely to achieve broad reimbursement. Patent expiry around leading PD-1 franchises, biosimilar development, national price negotiation and payer restrictions will place sustained pressure on ASP. Competition will also come from antibody-drug conjugates, targeted therapies, radioligand treatments and biomarker-selected combination regimens.
This report is a detailed and comprehensive analysis for global Checkpoint Inhibitors for Treating Cancer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Checkpoint Target and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Checkpoint Inhibitors for Treating Cancer market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Checkpoint Inhibitors for Treating Cancer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Checkpoint Inhibitors for Treating Cancer market size and forecasts, by Checkpoint Target and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Checkpoint Inhibitors for Treating Cancer market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Checkpoint Inhibitors for Treating Cancer
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Checkpoint Inhibitors for Treating Cancer market is split by Checkpoint Target and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Checkpoint Target, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Checkpoint Target
- PD-1 Single-target Inhibitor
- PD-L1 Single-target Inhibitor
- CTLA-4 Single-target Inhibitor
- PD-1/LAG-3 Combination
- PD-1/CTLA-4 Dual Product
- Other Checkpoint-containing Product
- Monoclonal Antibody
- Bispecific Antibody
- Fixed-dose Antibody Combination
- Antibody Enzyme Combination
- Intravenous Liquid Concentrate
- Intravenous Lyophilized Powder
- Subcutaneous Ready-to-use Injection
- Lung Cancer
- Gastrointestinal Cancer
- Genitourinary Cancer
- Hepatobiliary Cancer
- Gynecologic Cancer
- Skin Cancer
- Breast Cancer
- Head and Neck Cancer
- Hematologic Malignancy
- Other Solid Tumors
- Merck & Co.
- Bristol Myers Squibb
- AstraZeneca
- Roche
- Regeneron Pharmaceuticals
- GSK
- Ono Pharmaceutical
- BeOne Medicines
- Merck KGaA
- Innovent Biologics
- Jiangsu Hengrui Pharmaceuticals
- Shanghai Junshi Biosciences
- Akeso
- Shanghai Henlius Biotech
- Incyte
- Sino Biopharmaceutical
- BIOCAD
- Alphamab Oncology
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Checkpoint Inhibitors for Treating Cancer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Checkpoint Inhibitors for Treating Cancer, with price, sales quantity, revenue, and global market share of Checkpoint Inhibitors for Treating Cancer from 2021 to 2026.
Chapter 3, the Checkpoint Inhibitors for Treating Cancer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Checkpoint Inhibitors for Treating Cancer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Checkpoint Target and by Application, with sales market share and growth rate by Checkpoint Target, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Checkpoint Inhibitors for Treating Cancer market forecast, by regions, by Checkpoint Target, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Checkpoint Inhibitors for Treating Cancer.
Chapter 14 and 15, to describe Checkpoint Inhibitors for Treating Cancer sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Checkpoint Target
1.3.1 Overview: Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Checkpoint Target: 2021 Versus 2025 Versus 2032
1.3.2 PD-1 Single-target Inhibitor
1.3.3 PD-L1 Single-target Inhibitor
1.3.4 CTLA-4 Single-target Inhibitor
1.3.5 PD-1/LAG-3 Combination
1.3.6 PD-1/CTLA-4 Dual Product
1.3.7 Other Checkpoint-containing Product
1.4 Market Analysis by Molecular Format
1.4.1 Overview: Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Molecular Format: 2021 Versus 2025 Versus 2032
1.4.2 Monoclonal Antibody
1.4.3 Bispecific Antibody
1.4.4 Fixed-dose Antibody Combination
1.4.5 Antibody Enzyme Combination
1.5 Market Analysis by Dosage Form
1.5.1 Overview: Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
1.5.2 Intravenous Liquid Concentrate
1.5.3 Intravenous Lyophilized Powder
1.5.4 Subcutaneous Ready-to-use Injection
1.6 Market Analysis by Application
1.6.1 Overview: Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Lung Cancer
1.6.3 Gastrointestinal Cancer
1.6.4 Genitourinary Cancer
1.6.5 Hepatobiliary Cancer
1.6.6 Gynecologic Cancer
1.6.7 Skin Cancer
1.6.8 Breast Cancer
1.6.9 Head and Neck Cancer
1.6.10 Hematologic Malignancy
1.7 Global Checkpoint Inhibitors for Treating Cancer Market Size & Forecast
1.7.1 Global Checkpoint Inhibitors for Treating Cancer Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Checkpoint Inhibitors for Treating Cancer Sales Quantity (2021-2032)
1.7.3 Global Checkpoint Inhibitors for Treating Cancer Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Merck & Co.
2.1.1 Merck & Co. Details
2.1.2 Merck & Co. Major Business
2.1.3 Merck & Co. Checkpoint Inhibitors for Treating Cancer Product and Services
2.1.4 Merck & Co. Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Merck & Co. Recent Developments/Updates
2.2 Bristol Myers Squibb
2.2.1 Bristol Myers Squibb Details
2.2.2 Bristol Myers Squibb Major Business
2.2.3 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product and Services
2.2.4 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Bristol Myers Squibb Recent Developments/Updates
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Checkpoint Inhibitors for Treating Cancer Product and Services
2.3.4 AstraZeneca Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 AstraZeneca Recent Developments/Updates
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Checkpoint Inhibitors for Treating Cancer Product and Services
2.4.4 Roche Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Roche Recent Developments/Updates
2.5 Regeneron Pharmaceuticals
2.5.1 Regeneron Pharmaceuticals Details
2.5.2 Regeneron Pharmaceuticals Major Business
2.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
2.5.4 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
2.6 GSK
2.6.1 GSK Details
2.6.2 GSK Major Business
2.6.3 GSK Checkpoint Inhibitors for Treating Cancer Product and Services
2.6.4 GSK Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 GSK Recent Developments/Updates
2.7 Ono Pharmaceutical
2.7.1 Ono Pharmaceutical Details
2.7.2 Ono Pharmaceutical Major Business
2.7.3 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
2.7.4 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Ono Pharmaceutical Recent Developments/Updates
2.8 BeOne Medicines
2.8.1 BeOne Medicines Details
2.8.2 BeOne Medicines Major Business
2.8.3 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product and Services
2.8.4 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 BeOne Medicines Recent Developments/Updates
2.9 Merck KGaA
2.9.1 Merck KGaA Details
2.9.2 Merck KGaA Major Business
2.9.3 Merck KGaA Checkpoint Inhibitors for Treating Cancer Product and Services
2.9.4 Merck KGaA Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Merck KGaA Recent Developments/Updates
2.10 Innovent Biologics
2.10.1 Innovent Biologics Details
2.10.2 Innovent Biologics Major Business
2.10.3 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product and Services
2.10.4 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Innovent Biologics Recent Developments/Updates
2.11 Jiangsu Hengrui Pharmaceuticals
2.11.1 Jiangsu Hengrui Pharmaceuticals Details
2.11.2 Jiangsu Hengrui Pharmaceuticals Major Business
2.11.3 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
2.11.4 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
2.12 Shanghai Junshi Biosciences
2.12.1 Shanghai Junshi Biosciences Details
2.12.2 Shanghai Junshi Biosciences Major Business
2.12.3 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product and Services
2.12.4 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Shanghai Junshi Biosciences Recent Developments/Updates
2.13 Akeso
2.13.1 Akeso Details
2.13.2 Akeso Major Business
2.13.3 Akeso Checkpoint Inhibitors for Treating Cancer Product and Services
2.13.4 Akeso Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Akeso Recent Developments/Updates
2.14 Shanghai Henlius Biotech
2.14.1 Shanghai Henlius Biotech Details
2.14.2 Shanghai Henlius Biotech Major Business
2.14.3 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product and Services
2.14.4 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Shanghai Henlius Biotech Recent Developments/Updates
2.15 Incyte
2.15.1 Incyte Details
2.15.2 Incyte Major Business
2.15.3 Incyte Checkpoint Inhibitors for Treating Cancer Product and Services
2.15.4 Incyte Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Incyte Recent Developments/Updates
2.16 Sino Biopharmaceutical
2.16.1 Sino Biopharmaceutical Details
2.16.2 Sino Biopharmaceutical Major Business
2.16.3 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
2.16.4 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Sino Biopharmaceutical Recent Developments/Updates
2.17 BIOCAD
2.17.1 BIOCAD Details
2.17.2 BIOCAD Major Business
2.17.3 BIOCAD Checkpoint Inhibitors for Treating Cancer Product and Services
2.17.4 BIOCAD Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 BIOCAD Recent Developments/Updates
2.18 Alphamab Oncology
2.18.1 Alphamab Oncology Details
2.18.2 Alphamab Oncology Major Business
2.18.3 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product and Services
2.18.4 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Alphamab Oncology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: CHECKPOINT INHIBITORS FOR TREATING CANCER BY MANUFACTURER
3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Manufacturer (2021-2026)
3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2021-2026)
3.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Checkpoint Inhibitors for Treating Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share in 2025
3.4.3 Top 6 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share in 2025
3.5 Checkpoint Inhibitors for Treating Cancer Market: Overall Company Footprint Analysis
3.5.1 Checkpoint Inhibitors for Treating Cancer Market: Region Footprint
3.5.2 Checkpoint Inhibitors for Treating Cancer Market: Company Product Type Footprint
3.5.3 Checkpoint Inhibitors for Treating Cancer Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Checkpoint Inhibitors for Treating Cancer Market Size by Region
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2021-2032)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2021-2032)
4.1.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Region (2021-2032)
4.2 North America Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032)
4.3 Europe Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032)
4.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032)
4.5 South America Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032)
4.6 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032)
5 MARKET SEGMENT BY CHECKPOINT TARGET
5.1 Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
5.2 Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Checkpoint Target (2021-2032)
5.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
6.2 Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application (2021-2032)
6.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
7.2 North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
7.3 North America Checkpoint Inhibitors for Treating Cancer Market Size by Country
7.3.1 North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2032)
7.3.2 North America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
8.2 Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
8.3 Europe Checkpoint Inhibitors for Treating Cancer Market Size by Country
8.3.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2032)
8.3.2 Europe Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
9.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size by Region
9.3.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
10.2 South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
10.3 South America Checkpoint Inhibitors for Treating Cancer Market Size by Country
10.3.1 South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2032)
10.3.2 South America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
11.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Market Size by Country
11.3.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Checkpoint Inhibitors for Treating Cancer Market Drivers
12.2 Checkpoint Inhibitors for Treating Cancer Market Restraints
12.3 Checkpoint Inhibitors for Treating Cancer Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Checkpoint Inhibitors for Treating Cancer and Key Manufacturers
13.2 Manufacturing Costs Percentage of Checkpoint Inhibitors for Treating Cancer
13.3 Checkpoint Inhibitors for Treating Cancer Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Checkpoint Inhibitors for Treating Cancer Typical Distributors
14.3 Checkpoint Inhibitors for Treating Cancer Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Checkpoint Target
1.3.1 Overview: Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Checkpoint Target: 2021 Versus 2025 Versus 2032
1.3.2 PD-1 Single-target Inhibitor
1.3.3 PD-L1 Single-target Inhibitor
1.3.4 CTLA-4 Single-target Inhibitor
1.3.5 PD-1/LAG-3 Combination
1.3.6 PD-1/CTLA-4 Dual Product
1.3.7 Other Checkpoint-containing Product
1.4 Market Analysis by Molecular Format
1.4.1 Overview: Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Molecular Format: 2021 Versus 2025 Versus 2032
1.4.2 Monoclonal Antibody
1.4.3 Bispecific Antibody
1.4.4 Fixed-dose Antibody Combination
1.4.5 Antibody Enzyme Combination
1.5 Market Analysis by Dosage Form
1.5.1 Overview: Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
1.5.2 Intravenous Liquid Concentrate
1.5.3 Intravenous Lyophilized Powder
1.5.4 Subcutaneous Ready-to-use Injection
1.6 Market Analysis by Application
1.6.1 Overview: Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Lung Cancer
1.6.3 Gastrointestinal Cancer
1.6.4 Genitourinary Cancer
1.6.5 Hepatobiliary Cancer
1.6.6 Gynecologic Cancer
1.6.7 Skin Cancer
1.6.8 Breast Cancer
1.6.9 Head and Neck Cancer
1.6.10 Hematologic Malignancy
1.7 Global Checkpoint Inhibitors for Treating Cancer Market Size & Forecast
1.7.1 Global Checkpoint Inhibitors for Treating Cancer Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Checkpoint Inhibitors for Treating Cancer Sales Quantity (2021-2032)
1.7.3 Global Checkpoint Inhibitors for Treating Cancer Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Merck & Co.
2.1.1 Merck & Co. Details
2.1.2 Merck & Co. Major Business
2.1.3 Merck & Co. Checkpoint Inhibitors for Treating Cancer Product and Services
2.1.4 Merck & Co. Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Merck & Co. Recent Developments/Updates
2.2 Bristol Myers Squibb
2.2.1 Bristol Myers Squibb Details
2.2.2 Bristol Myers Squibb Major Business
2.2.3 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product and Services
2.2.4 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Bristol Myers Squibb Recent Developments/Updates
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Checkpoint Inhibitors for Treating Cancer Product and Services
2.3.4 AstraZeneca Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 AstraZeneca Recent Developments/Updates
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Checkpoint Inhibitors for Treating Cancer Product and Services
2.4.4 Roche Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Roche Recent Developments/Updates
2.5 Regeneron Pharmaceuticals
2.5.1 Regeneron Pharmaceuticals Details
2.5.2 Regeneron Pharmaceuticals Major Business
2.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
2.5.4 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
2.6 GSK
2.6.1 GSK Details
2.6.2 GSK Major Business
2.6.3 GSK Checkpoint Inhibitors for Treating Cancer Product and Services
2.6.4 GSK Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 GSK Recent Developments/Updates
2.7 Ono Pharmaceutical
2.7.1 Ono Pharmaceutical Details
2.7.2 Ono Pharmaceutical Major Business
2.7.3 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
2.7.4 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Ono Pharmaceutical Recent Developments/Updates
2.8 BeOne Medicines
2.8.1 BeOne Medicines Details
2.8.2 BeOne Medicines Major Business
2.8.3 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product and Services
2.8.4 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 BeOne Medicines Recent Developments/Updates
2.9 Merck KGaA
2.9.1 Merck KGaA Details
2.9.2 Merck KGaA Major Business
2.9.3 Merck KGaA Checkpoint Inhibitors for Treating Cancer Product and Services
2.9.4 Merck KGaA Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Merck KGaA Recent Developments/Updates
2.10 Innovent Biologics
2.10.1 Innovent Biologics Details
2.10.2 Innovent Biologics Major Business
2.10.3 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product and Services
2.10.4 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Innovent Biologics Recent Developments/Updates
2.11 Jiangsu Hengrui Pharmaceuticals
2.11.1 Jiangsu Hengrui Pharmaceuticals Details
2.11.2 Jiangsu Hengrui Pharmaceuticals Major Business
2.11.3 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
2.11.4 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
2.12 Shanghai Junshi Biosciences
2.12.1 Shanghai Junshi Biosciences Details
2.12.2 Shanghai Junshi Biosciences Major Business
2.12.3 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product and Services
2.12.4 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Shanghai Junshi Biosciences Recent Developments/Updates
2.13 Akeso
2.13.1 Akeso Details
2.13.2 Akeso Major Business
2.13.3 Akeso Checkpoint Inhibitors for Treating Cancer Product and Services
2.13.4 Akeso Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Akeso Recent Developments/Updates
2.14 Shanghai Henlius Biotech
2.14.1 Shanghai Henlius Biotech Details
2.14.2 Shanghai Henlius Biotech Major Business
2.14.3 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product and Services
2.14.4 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Shanghai Henlius Biotech Recent Developments/Updates
2.15 Incyte
2.15.1 Incyte Details
2.15.2 Incyte Major Business
2.15.3 Incyte Checkpoint Inhibitors for Treating Cancer Product and Services
2.15.4 Incyte Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Incyte Recent Developments/Updates
2.16 Sino Biopharmaceutical
2.16.1 Sino Biopharmaceutical Details
2.16.2 Sino Biopharmaceutical Major Business
2.16.3 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
2.16.4 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Sino Biopharmaceutical Recent Developments/Updates
2.17 BIOCAD
2.17.1 BIOCAD Details
2.17.2 BIOCAD Major Business
2.17.3 BIOCAD Checkpoint Inhibitors for Treating Cancer Product and Services
2.17.4 BIOCAD Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 BIOCAD Recent Developments/Updates
2.18 Alphamab Oncology
2.18.1 Alphamab Oncology Details
2.18.2 Alphamab Oncology Major Business
2.18.3 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product and Services
2.18.4 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Alphamab Oncology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: CHECKPOINT INHIBITORS FOR TREATING CANCER BY MANUFACTURER
3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Manufacturer (2021-2026)
3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2021-2026)
3.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Checkpoint Inhibitors for Treating Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share in 2025
3.4.3 Top 6 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share in 2025
3.5 Checkpoint Inhibitors for Treating Cancer Market: Overall Company Footprint Analysis
3.5.1 Checkpoint Inhibitors for Treating Cancer Market: Region Footprint
3.5.2 Checkpoint Inhibitors for Treating Cancer Market: Company Product Type Footprint
3.5.3 Checkpoint Inhibitors for Treating Cancer Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Checkpoint Inhibitors for Treating Cancer Market Size by Region
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2021-2032)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2021-2032)
4.1.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Region (2021-2032)
4.2 North America Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032)
4.3 Europe Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032)
4.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032)
4.5 South America Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032)
4.6 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032)
5 MARKET SEGMENT BY CHECKPOINT TARGET
5.1 Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
5.2 Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Checkpoint Target (2021-2032)
5.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
6.2 Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application (2021-2032)
6.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
7.2 North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
7.3 North America Checkpoint Inhibitors for Treating Cancer Market Size by Country
7.3.1 North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2032)
7.3.2 North America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
8.2 Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
8.3 Europe Checkpoint Inhibitors for Treating Cancer Market Size by Country
8.3.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2032)
8.3.2 Europe Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
9.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size by Region
9.3.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
10.2 South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
10.3 South America Checkpoint Inhibitors for Treating Cancer Market Size by Country
10.3.1 South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2032)
10.3.2 South America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2032)
11.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Market Size by Country
11.3.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Checkpoint Inhibitors for Treating Cancer Market Drivers
12.2 Checkpoint Inhibitors for Treating Cancer Market Restraints
12.3 Checkpoint Inhibitors for Treating Cancer Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Checkpoint Inhibitors for Treating Cancer and Key Manufacturers
13.2 Manufacturing Costs Percentage of Checkpoint Inhibitors for Treating Cancer
13.3 Checkpoint Inhibitors for Treating Cancer Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Checkpoint Inhibitors for Treating Cancer Typical Distributors
14.3 Checkpoint Inhibitors for Treating Cancer Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Checkpoint Target, (USD Million), 2021 & 2025 & 2032
Table 2. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Molecular Format, (USD Million), 2021 & 2025 & 2032
Table 3. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 4. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 6. Merck & Co. Major Business
Table 7. Merck & Co. Checkpoint Inhibitors for Treating Cancer Product and Services
Table 8. Merck & Co. Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Merck & Co. Recent Developments/Updates
Table 10. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 11. Bristol Myers Squibb Major Business
Table 12. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product and Services
Table 13. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Bristol Myers Squibb Recent Developments/Updates
Table 15. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 16. AstraZeneca Major Business
Table 17. AstraZeneca Checkpoint Inhibitors for Treating Cancer Product and Services
Table 18. AstraZeneca Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. AstraZeneca Recent Developments/Updates
Table 20. Roche Basic Information, Manufacturing Base and Competitors
Table 21. Roche Major Business
Table 22. Roche Checkpoint Inhibitors for Treating Cancer Product and Services
Table 23. Roche Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Roche Recent Developments/Updates
Table 25. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 26. Regeneron Pharmaceuticals Major Business
Table 27. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
Table 28. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. Regeneron Pharmaceuticals Recent Developments/Updates
Table 30. GSK Basic Information, Manufacturing Base and Competitors
Table 31. GSK Major Business
Table 32. GSK Checkpoint Inhibitors for Treating Cancer Product and Services
Table 33. GSK Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. GSK Recent Developments/Updates
Table 35. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 36. Ono Pharmaceutical Major Business
Table 37. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
Table 38. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Ono Pharmaceutical Recent Developments/Updates
Table 40. BeOne Medicines Basic Information, Manufacturing Base and Competitors
Table 41. BeOne Medicines Major Business
Table 42. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product and Services
Table 43. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. BeOne Medicines Recent Developments/Updates
Table 45. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 46. Merck KGaA Major Business
Table 47. Merck KGaA Checkpoint Inhibitors for Treating Cancer Product and Services
Table 48. Merck KGaA Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. Merck KGaA Recent Developments/Updates
Table 50. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 51. Innovent Biologics Major Business
Table 52. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product and Services
Table 53. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. Innovent Biologics Recent Developments/Updates
Table 55. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 56. Jiangsu Hengrui Pharmaceuticals Major Business
Table 57. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
Table 58. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 59. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 60. Shanghai Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 61. Shanghai Junshi Biosciences Major Business
Table 62. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product and Services
Table 63. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 64. Shanghai Junshi Biosciences Recent Developments/Updates
Table 65. Akeso Basic Information, Manufacturing Base and Competitors
Table 66. Akeso Major Business
Table 67. Akeso Checkpoint Inhibitors for Treating Cancer Product and Services
Table 68. Akeso Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 69. Akeso Recent Developments/Updates
Table 70. Shanghai Henlius Biotech Basic Information, Manufacturing Base and Competitors
Table 71. Shanghai Henlius Biotech Major Business
Table 72. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product and Services
Table 73. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 74. Shanghai Henlius Biotech Recent Developments/Updates
Table 75. Incyte Basic Information, Manufacturing Base and Competitors
Table 76. Incyte Major Business
Table 77. Incyte Checkpoint Inhibitors for Treating Cancer Product and Services
Table 78. Incyte Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Incyte Recent Developments/Updates
Table 80. Sino Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 81. Sino Biopharmaceutical Major Business
Table 82. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
Table 83. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 84. Sino Biopharmaceutical Recent Developments/Updates
Table 85. BIOCAD Basic Information, Manufacturing Base and Competitors
Table 86. BIOCAD Major Business
Table 87. BIOCAD Checkpoint Inhibitors for Treating Cancer Product and Services
Table 88. BIOCAD Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 89. BIOCAD Recent Developments/Updates
Table 90. Alphamab Oncology Basic Information, Manufacturing Base and Competitors
Table 91. Alphamab Oncology Major Business
Table 92. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product and Services
Table 93. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 94. Alphamab Oncology Recent Developments/Updates
Table 95. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Manufacturer (2021-2026) & (K Units)
Table 96. Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2021-2026) & (USD Million)
Table 97. Global Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 98. Market Position of Manufacturers in Checkpoint Inhibitors for Treating Cancer, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 99. Head Office and Checkpoint Inhibitors for Treating Cancer Production Site of Key Manufacturer
Table 100. Checkpoint Inhibitors for Treating Cancer Market: Company Product Type Footprint
Table 101. Checkpoint Inhibitors for Treating Cancer Market: Company Product Application Footprint
Table 102. Checkpoint Inhibitors for Treating Cancer New Market Entrants and Barriers to Market Entry
Table 103. Checkpoint Inhibitors for Treating Cancer Mergers, Acquisition, Agreements, and Collaborations
Table 104. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 105. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2021-2026) & (K Units)
Table 106. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2027-2032) & (K Units)
Table 107. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2021-2026) & (USD Million)
Table 108. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2027-2032) & (USD Million)
Table 109. Global Checkpoint Inhibitors for Treating Cancer Average Price by Region (2021-2026) & (US$/Unit)
Table 110. Global Checkpoint Inhibitors for Treating Cancer Average Price by Region (2027-2032) & (US$/Unit)
Table 111. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 112. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 113. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Checkpoint Target (2021-2026) & (USD Million)
Table 114. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Checkpoint Target (2027-2032) & (USD Million)
Table 115. Global Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2026) & (US$/Unit)
Table 116. Global Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2027-2032) & (US$/Unit)
Table 117. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 118. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 119. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application (2021-2026) & (USD Million)
Table 120. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application (2027-2032) & (USD Million)
Table 121. Global Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2026) & (US$/Unit)
Table 122. Global Checkpoint Inhibitors for Treating Cancer Average Price by Application (2027-2032) & (US$/Unit)
Table 123. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 124. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 125. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 126. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 127. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2026) & (K Units)
Table 128. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2027-2032) & (K Units)
Table 129. North America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2026) & (USD Million)
Table 130. North America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2027-2032) & (USD Million)
Table 131. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 132. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 133. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 134. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 135. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2026) & (K Units)
Table 136. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2027-2032) & (K Units)
Table 137. Europe Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2026) & (USD Million)
Table 138. Europe Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2027-2032) & (USD Million)
Table 139. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 140. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 141. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 142. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 143. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2021-2026) & (K Units)
Table 144. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2027-2032) & (K Units)
Table 145. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2021-2026) & (USD Million)
Table 146. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2027-2032) & (USD Million)
Table 147. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 148. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 149. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 150. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 151. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2026) & (K Units)
Table 152. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2027-2032) & (K Units)
Table 153. South America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2026) & (USD Million)
Table 154. South America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2027-2032) & (USD Million)
Table 155. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 156. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 157. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 158. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 159. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2026) & (K Units)
Table 160. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2027-2032) & (K Units)
Table 161. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2026) & (USD Million)
Table 162. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2027-2032) & (USD Million)
Table 163. Checkpoint Inhibitors for Treating Cancer Raw Material
Table 164. Key Manufacturers of Checkpoint Inhibitors for Treating Cancer Raw Materials
Table 165. Checkpoint Inhibitors for Treating Cancer Typical Distributors
Table 166. Checkpoint Inhibitors for Treating Cancer Typical Customers
Table 1. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Checkpoint Target, (USD Million), 2021 & 2025 & 2032
Table 2. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Molecular Format, (USD Million), 2021 & 2025 & 2032
Table 3. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 4. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 6. Merck & Co. Major Business
Table 7. Merck & Co. Checkpoint Inhibitors for Treating Cancer Product and Services
Table 8. Merck & Co. Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Merck & Co. Recent Developments/Updates
Table 10. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 11. Bristol Myers Squibb Major Business
Table 12. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product and Services
Table 13. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Bristol Myers Squibb Recent Developments/Updates
Table 15. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 16. AstraZeneca Major Business
Table 17. AstraZeneca Checkpoint Inhibitors for Treating Cancer Product and Services
Table 18. AstraZeneca Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. AstraZeneca Recent Developments/Updates
Table 20. Roche Basic Information, Manufacturing Base and Competitors
Table 21. Roche Major Business
Table 22. Roche Checkpoint Inhibitors for Treating Cancer Product and Services
Table 23. Roche Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Roche Recent Developments/Updates
Table 25. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 26. Regeneron Pharmaceuticals Major Business
Table 27. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
Table 28. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. Regeneron Pharmaceuticals Recent Developments/Updates
Table 30. GSK Basic Information, Manufacturing Base and Competitors
Table 31. GSK Major Business
Table 32. GSK Checkpoint Inhibitors for Treating Cancer Product and Services
Table 33. GSK Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. GSK Recent Developments/Updates
Table 35. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 36. Ono Pharmaceutical Major Business
Table 37. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
Table 38. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Ono Pharmaceutical Recent Developments/Updates
Table 40. BeOne Medicines Basic Information, Manufacturing Base and Competitors
Table 41. BeOne Medicines Major Business
Table 42. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product and Services
Table 43. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. BeOne Medicines Recent Developments/Updates
Table 45. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 46. Merck KGaA Major Business
Table 47. Merck KGaA Checkpoint Inhibitors for Treating Cancer Product and Services
Table 48. Merck KGaA Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. Merck KGaA Recent Developments/Updates
Table 50. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 51. Innovent Biologics Major Business
Table 52. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product and Services
Table 53. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. Innovent Biologics Recent Developments/Updates
Table 55. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 56. Jiangsu Hengrui Pharmaceuticals Major Business
Table 57. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
Table 58. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 59. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 60. Shanghai Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 61. Shanghai Junshi Biosciences Major Business
Table 62. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product and Services
Table 63. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 64. Shanghai Junshi Biosciences Recent Developments/Updates
Table 65. Akeso Basic Information, Manufacturing Base and Competitors
Table 66. Akeso Major Business
Table 67. Akeso Checkpoint Inhibitors for Treating Cancer Product and Services
Table 68. Akeso Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 69. Akeso Recent Developments/Updates
Table 70. Shanghai Henlius Biotech Basic Information, Manufacturing Base and Competitors
Table 71. Shanghai Henlius Biotech Major Business
Table 72. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product and Services
Table 73. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 74. Shanghai Henlius Biotech Recent Developments/Updates
Table 75. Incyte Basic Information, Manufacturing Base and Competitors
Table 76. Incyte Major Business
Table 77. Incyte Checkpoint Inhibitors for Treating Cancer Product and Services
Table 78. Incyte Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Incyte Recent Developments/Updates
Table 80. Sino Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 81. Sino Biopharmaceutical Major Business
Table 82. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
Table 83. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 84. Sino Biopharmaceutical Recent Developments/Updates
Table 85. BIOCAD Basic Information, Manufacturing Base and Competitors
Table 86. BIOCAD Major Business
Table 87. BIOCAD Checkpoint Inhibitors for Treating Cancer Product and Services
Table 88. BIOCAD Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 89. BIOCAD Recent Developments/Updates
Table 90. Alphamab Oncology Basic Information, Manufacturing Base and Competitors
Table 91. Alphamab Oncology Major Business
Table 92. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product and Services
Table 93. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 94. Alphamab Oncology Recent Developments/Updates
Table 95. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Manufacturer (2021-2026) & (K Units)
Table 96. Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2021-2026) & (USD Million)
Table 97. Global Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 98. Market Position of Manufacturers in Checkpoint Inhibitors for Treating Cancer, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 99. Head Office and Checkpoint Inhibitors for Treating Cancer Production Site of Key Manufacturer
Table 100. Checkpoint Inhibitors for Treating Cancer Market: Company Product Type Footprint
Table 101. Checkpoint Inhibitors for Treating Cancer Market: Company Product Application Footprint
Table 102. Checkpoint Inhibitors for Treating Cancer New Market Entrants and Barriers to Market Entry
Table 103. Checkpoint Inhibitors for Treating Cancer Mergers, Acquisition, Agreements, and Collaborations
Table 104. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 105. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2021-2026) & (K Units)
Table 106. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2027-2032) & (K Units)
Table 107. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2021-2026) & (USD Million)
Table 108. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2027-2032) & (USD Million)
Table 109. Global Checkpoint Inhibitors for Treating Cancer Average Price by Region (2021-2026) & (US$/Unit)
Table 110. Global Checkpoint Inhibitors for Treating Cancer Average Price by Region (2027-2032) & (US$/Unit)
Table 111. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 112. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 113. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Checkpoint Target (2021-2026) & (USD Million)
Table 114. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Checkpoint Target (2027-2032) & (USD Million)
Table 115. Global Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2026) & (US$/Unit)
Table 116. Global Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2027-2032) & (US$/Unit)
Table 117. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 118. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 119. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application (2021-2026) & (USD Million)
Table 120. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application (2027-2032) & (USD Million)
Table 121. Global Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2026) & (US$/Unit)
Table 122. Global Checkpoint Inhibitors for Treating Cancer Average Price by Application (2027-2032) & (US$/Unit)
Table 123. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 124. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 125. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 126. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 127. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2026) & (K Units)
Table 128. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2027-2032) & (K Units)
Table 129. North America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2026) & (USD Million)
Table 130. North America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2027-2032) & (USD Million)
Table 131. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 132. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 133. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 134. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 135. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2026) & (K Units)
Table 136. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2027-2032) & (K Units)
Table 137. Europe Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2026) & (USD Million)
Table 138. Europe Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2027-2032) & (USD Million)
Table 139. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 140. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 141. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 142. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 143. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2021-2026) & (K Units)
Table 144. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity by Region (2027-2032) & (K Units)
Table 145. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2021-2026) & (USD Million)
Table 146. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value by Region (2027-2032) & (USD Million)
Table 147. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 148. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 149. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 150. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 151. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2026) & (K Units)
Table 152. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2027-2032) & (K Units)
Table 153. South America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2026) & (USD Million)
Table 154. South America Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2027-2032) & (USD Million)
Table 155. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2021-2026) & (K Units)
Table 156. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Checkpoint Target (2027-2032) & (K Units)
Table 157. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2021-2026) & (K Units)
Table 158. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Application (2027-2032) & (K Units)
Table 159. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2021-2026) & (K Units)
Table 160. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity by Country (2027-2032) & (K Units)
Table 161. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2021-2026) & (USD Million)
Table 162. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value by Country (2027-2032) & (USD Million)
Table 163. Checkpoint Inhibitors for Treating Cancer Raw Material
Table 164. Key Manufacturers of Checkpoint Inhibitors for Treating Cancer Raw Materials
Table 165. Checkpoint Inhibitors for Treating Cancer Typical Distributors
Table 166. Checkpoint Inhibitors for Treating Cancer Typical Customers
LIST OF FIGURES
Figure 1. Checkpoint Inhibitors for Treating Cancer Picture
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Revenue by Checkpoint Target, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Checkpoint Target in 2025
Figure 4. PD-1 Single-target Inhibitor Examples
Figure 5. PD-L1 Single-target Inhibitor Examples
Figure 6. CTLA-4 Single-target Inhibitor Examples
Figure 7. PD-1/LAG-3 Combination Examples
Figure 8. PD-1/CTLA-4 Dual Product Examples
Figure 9. Other Checkpoint-containing Product Examples
Figure 10. Global Checkpoint Inhibitors for Treating Cancer Revenue by Molecular Format, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Molecular Format in 2025
Figure 12. Monoclonal Antibody Examples
Figure 13. Bispecific Antibody Examples
Figure 14. Fixed-dose Antibody Combination Examples
Figure 15. Antibody Enzyme Combination Examples
Figure 16. Global Checkpoint Inhibitors for Treating Cancer Revenue by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Dosage Form in 2025
Figure 18. Intravenous Liquid Concentrate Examples
Figure 19. Intravenous Lyophilized Powder Examples
Figure 20. Subcutaneous Ready-to-use Injection Examples
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 22. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application in 2025
Figure 23. Lung Cancer Examples
Figure 24. Gastrointestinal Cancer Examples
Figure 25. Genitourinary Cancer Examples
Figure 26. Hepatobiliary Cancer Examples
Figure 27. Gynecologic Cancer Examples
Figure 28. Skin Cancer Examples
Figure 29. Breast Cancer Examples
Figure 30. Head and Neck Cancer Examples
Figure 31. Head and Neck Cancer Examples
Figure 32. Global Checkpoint Inhibitors for Treating Cancer Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 33. Global Checkpoint Inhibitors for Treating Cancer Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 34. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity (2021-2032) & (K Units)
Figure 35. Global Checkpoint Inhibitors for Treating Cancer Price (2021-2032) & (US$/Unit)
Figure 36. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Manufacturer in 2025
Figure 37. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2025
Figure 38. Producer Shipments of Checkpoint Inhibitors for Treating Cancer by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 39. Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer (Revenue) Market Share in 2025
Figure 40. Top 6 Checkpoint Inhibitors for Treating Cancer Manufacturer (Revenue) Market Share in 2025
Figure 41. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Region (2021-2032)
Figure 42. Global Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Region (2021-2032)
Figure 43. North America Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 44. Europe Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 45. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 46. South America Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 47. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 48. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 49. Global Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Checkpoint Target (2021-2032)
Figure 50. Global Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2032) & (US$/Unit)
Figure 51. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 52. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2021-2032)
Figure 53. Global Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2032) & (US$/Unit)
Figure 54. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 55. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 56. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Country (2021-2032)
Figure 57. North America Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Country (2021-2032)
Figure 58. United States Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 59. Canada Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 60. Mexico Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 61. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 62. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 63. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Country (2021-2032)
Figure 64. Europe Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Country (2021-2032)
Figure 65. Germany Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 66. France Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 67. United Kingdom Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 68. Russia Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 69. Italy Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 70. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 71. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 72. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Region (2021-2032)
Figure 73. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Region (2021-2032)
Figure 74. China Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 75. Japan Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 76. South Korea Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 77. India Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 78. Southeast Asia Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 79. Australia Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 80. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 81. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 82. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Country (2021-2032)
Figure 83. South America Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Country (2021-2032)
Figure 84. Brazil Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 85. Argentina Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 86. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 87. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 88. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Country (2021-2032)
Figure 89. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Country (2021-2032)
Figure 90. Turkey Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 91. Egypt Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 92. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 93. South Africa Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 94. Checkpoint Inhibitors for Treating Cancer Market Drivers
Figure 95. Checkpoint Inhibitors for Treating Cancer Market Restraints
Figure 96. Checkpoint Inhibitors for Treating Cancer Market Trends
Figure 97. Porters Five Forces Analysis
Figure 98. Manufacturing Cost Structure Analysis of Checkpoint Inhibitors for Treating Cancer in 2025
Figure 99. Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
Figure 100. Checkpoint Inhibitors for Treating Cancer Industrial Chain
Figure 101. Sales Channel: Direct to End-User vs Distributors
Figure 102. Direct Channel Pros & Cons
Figure 103. Indirect Channel Pros & Cons
Figure 104. Methodology
Figure 105. Research Process and Data Source
Figure 1. Checkpoint Inhibitors for Treating Cancer Picture
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Revenue by Checkpoint Target, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Checkpoint Target in 2025
Figure 4. PD-1 Single-target Inhibitor Examples
Figure 5. PD-L1 Single-target Inhibitor Examples
Figure 6. CTLA-4 Single-target Inhibitor Examples
Figure 7. PD-1/LAG-3 Combination Examples
Figure 8. PD-1/CTLA-4 Dual Product Examples
Figure 9. Other Checkpoint-containing Product Examples
Figure 10. Global Checkpoint Inhibitors for Treating Cancer Revenue by Molecular Format, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Molecular Format in 2025
Figure 12. Monoclonal Antibody Examples
Figure 13. Bispecific Antibody Examples
Figure 14. Fixed-dose Antibody Combination Examples
Figure 15. Antibody Enzyme Combination Examples
Figure 16. Global Checkpoint Inhibitors for Treating Cancer Revenue by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Dosage Form in 2025
Figure 18. Intravenous Liquid Concentrate Examples
Figure 19. Intravenous Lyophilized Powder Examples
Figure 20. Subcutaneous Ready-to-use Injection Examples
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 22. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application in 2025
Figure 23. Lung Cancer Examples
Figure 24. Gastrointestinal Cancer Examples
Figure 25. Genitourinary Cancer Examples
Figure 26. Hepatobiliary Cancer Examples
Figure 27. Gynecologic Cancer Examples
Figure 28. Skin Cancer Examples
Figure 29. Breast Cancer Examples
Figure 30. Head and Neck Cancer Examples
Figure 31. Head and Neck Cancer Examples
Figure 32. Global Checkpoint Inhibitors for Treating Cancer Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 33. Global Checkpoint Inhibitors for Treating Cancer Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 34. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity (2021-2032) & (K Units)
Figure 35. Global Checkpoint Inhibitors for Treating Cancer Price (2021-2032) & (US$/Unit)
Figure 36. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Manufacturer in 2025
Figure 37. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2025
Figure 38. Producer Shipments of Checkpoint Inhibitors for Treating Cancer by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 39. Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer (Revenue) Market Share in 2025
Figure 40. Top 6 Checkpoint Inhibitors for Treating Cancer Manufacturer (Revenue) Market Share in 2025
Figure 41. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Region (2021-2032)
Figure 42. Global Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Region (2021-2032)
Figure 43. North America Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 44. Europe Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 45. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 46. South America Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 47. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 48. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 49. Global Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Checkpoint Target (2021-2032)
Figure 50. Global Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2032) & (US$/Unit)
Figure 51. Global Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 52. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2021-2032)
Figure 53. Global Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2032) & (US$/Unit)
Figure 54. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 55. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 56. North America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Country (2021-2032)
Figure 57. North America Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Country (2021-2032)
Figure 58. United States Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 59. Canada Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 60. Mexico Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 61. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 62. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 63. Europe Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Country (2021-2032)
Figure 64. Europe Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Country (2021-2032)
Figure 65. Germany Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 66. France Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 67. United Kingdom Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 68. Russia Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 69. Italy Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 70. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 71. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 72. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Region (2021-2032)
Figure 73. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Region (2021-2032)
Figure 74. China Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 75. Japan Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 76. South Korea Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 77. India Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 78. Southeast Asia Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 79. Australia Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 80. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 81. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 82. South America Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Country (2021-2032)
Figure 83. South America Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Country (2021-2032)
Figure 84. Brazil Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 85. Argentina Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 86. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Checkpoint Target (2021-2032)
Figure 87. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Application (2021-2032)
Figure 88. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Quantity Market Share by Country (2021-2032)
Figure 89. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Value Market Share by Country (2021-2032)
Figure 90. Turkey Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 91. Egypt Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 92. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 93. South Africa Checkpoint Inhibitors for Treating Cancer Consumption Value (2021-2032) & (USD Million)
Figure 94. Checkpoint Inhibitors for Treating Cancer Market Drivers
Figure 95. Checkpoint Inhibitors for Treating Cancer Market Restraints
Figure 96. Checkpoint Inhibitors for Treating Cancer Market Trends
Figure 97. Porters Five Forces Analysis
Figure 98. Manufacturing Cost Structure Analysis of Checkpoint Inhibitors for Treating Cancer in 2025
Figure 99. Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
Figure 100. Checkpoint Inhibitors for Treating Cancer Industrial Chain
Figure 101. Sales Channel: Direct to End-User vs Distributors
Figure 102. Direct Channel Pros & Cons
Figure 103. Indirect Channel Pros & Cons
Figure 104. Methodology
Figure 105. Research Process and Data Source
More Publications
EMEA Prostate Cancer Diagnostics Market by Manufacturers, Regions, Type and Application, Forecast to 2022
US$ 4,480.00
November 2017
119 pages
EMEA Cancer Treatment Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2022
US$ 4,480.00
October 2017
120 pages
Global Cancer Supportive Care Products Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
US$ 3,480.00
October 2018
134 pages
Global Prostate Cancer Diagnostics Market 2025 by Company, Regions, Type and Application, Forecast to 2031
US$ 3,480.00
June 2025
119 pages
EMEA Treated Distillate Aromatic Extract (TDAE) Market by Manufacturers, Regions, Type and Application, Forecast to 2022
US$ 4,480.00
October 2017
118 pages
